Littérature scientifique sur le sujet « Immune-related adverse effect »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Immune-related adverse effect ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Immune-related adverse effect"
Bangalore Kumar, Anagha, Alan Bryce, Prakash Vishnu, Svetomir Markovic et Marian McEvoy. « Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma ». SKIN The Journal of Cutaneous Medicine 5, no 2 (6 mars 2021) : 108–17. http://dx.doi.org/10.25251/skin.5.2.5.
Texte intégralWilliams, Kiersten J., Dennis W. Grauer, David W. Henry et Michelle L. Rockey. « Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors ». Journal of Oncology Pharmacy Practice 25, no 3 (9 décembre 2017) : 544–50. http://dx.doi.org/10.1177/1078155217744872.
Texte intégralMuir, Christopher A., Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang et Alexander M. Menzies. « Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment ». Journal of Clinical Endocrinology & ; Metabolism 106, no 9 (20 avril 2021) : e3704-e3713. http://dx.doi.org/10.1210/clinem/dgab263.
Texte intégralBansal, Aditi, Ankur Singla, Davinder Paul et Sukhjot Kaur. « Pembrolizumab-induced lichen planus : A rare immune-related adverse side effect ». Indian Dermatology Online Journal 14, no 3 (2023) : 391. http://dx.doi.org/10.4103/idoj.idoj_377_22.
Texte intégralLima, Gian, Adriana Kahn, Shashank Sama et Jacqueline Savage. « Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab ». Case Reports in Oncological Medicine 2019 (4 novembre 2019) : 1–2. http://dx.doi.org/10.1155/2019/7183747.
Texte intégralKim, Won Myung, Mun Su Park, Dong Hyun Seo, Jung Yun Lee et Jung Yoon Pyo. « Immune-related Adverse Effect after BNT162b2 Vaccination with Parallel Immune Checkpoint Inhibitor Therapy : A Case Report ». Korean Journal of Medicine 98, no 2 (1 avril 2023) : 93–97. http://dx.doi.org/10.3904/kjm.2023.98.2.93.
Texte intégralBrinzevich, Daria, Virginia Falvello, Michael D. Green et Alex Bryant. « Impact of commonly prescribed medications on immune-related adverse events. » Journal of Clinical Oncology 42, no 16_suppl (1 juin 2024) : e14704-e14704. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14704.
Texte intégralOu, Qiyun, Yunfang Yu, Haitao Zhong, Anlin Li, Yongjian Chen, HaiYu Zhou, Shaopeng Zheng, Luyu Huang et Herui Yao. « Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer. » Journal of Clinical Oncology 37, no 15_suppl (20 mai 2019) : e14087-e14087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14087.
Texte intégralHamatake, Kiyonori, et Kazuaki Kojima. « Initiatives for immune-related adverse events by the outpatient pharmacist clinic ». Trends in Immunotherapy 6, no 1 (10 janvier 2022) : 3. http://dx.doi.org/10.24294/ti.v6.i1.1385.
Texte intégralSakai, Miho, Yuki Haga, Michiyo Kambe, Koji Nishimura, Ayako Shingyouchi, Tatsuo Miyamura, Kenji Ito et al. « A case of immune-related adverse effect diffuse gastritis induced by nivolumab ». Progress of Digestive Endoscopy 98, no 1 (25 juin 2021) : 91–92. http://dx.doi.org/10.11641/pde.98.1_91.
Texte intégralThèses sur le sujet "Immune-related adverse effect"
L'Orphelin, Jean-Matthieu. « Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV ». Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC406.
Texte intégralBackground. Immune checkpoint inhibitors are the undisputed first-line treatment for stage IV melanoma, and are associated with adverse events, often immuno-related. Immune-related events are increasingly taken into account in therapeutic decisions, and there is a desire to individualize the management of patients with metastatic melanoma. A more detailed characterization of these events would enable better prediction of their occurrence and impact. Our knowledge of immuno-related events comes mainly from randomized phase III clinical trials, through the collection of safety data for the duration of the study. This does not allow us to identify late-onset safety signals, occurring long after the clinical trial, or rare safety signals not always reported in the publication. . Materials and methods. A safety meta-analysis conducted on randomized clinical trials from ClinicalTrials.gov aims to identify rare safety signals allowing greater comprehensiveness. We determined the type and incidence of rare events (represented by cardiovascular events) associated with exposure to immune checkpoint inhibitors in stage IV melanoma. Post-marketing studies have been carried out on three databases: RIC-Mel and Vigibase®, set up beforehand, and Melskintox, specifically set up to record cutaneous immune-related effects. These “real-life” studies make it possible to investigate the type, incidence and impact of dermatological immune-related events at risk of under-reporting, and to characterize all late-onset immune-related events late after the introduction of the immune checkpoint inhibitor, since follow-up from randomized clinical trials is too short to be informative. Finally, we discussed the safety of reintroducing an immune checkpoint inhibitor after an immuno-related event. Results. The meta-analysis enables us to identify some immuno-related events not initially identified in randomized clinical trials because they are rare and not systematically investigated, such as cardiovascular events. However, they can be serious as myocarditis and pericarditis. Some, such as dyslipidemia, suggest a long delay in onset, made possible by the extended overall survival of melanoma patients treated with immune checkpoint inhibitors. In real-life cohort studies, other severe late-onset events may occur long after from the initiation of treatment (after two years), affecting all organs. Patients with SSM melanoma appear to have a higher risk of late-onset adverse events. Certain frequent and rare serious immune-related events are imperfectly investigated, and the diversity of clinical presentations is poorly understood. The prognosis seems to differ depending on whether the cutaneous immuno-related effect is a benign inflammatory dermatosis, a pigmentary disorder, drug-related rash or bullous dermatosis. Finally, pharmacovigilance data on reintroduction vary according to the initial immune-related event, suggesting a higher recurrence rate for nephritis and cutaneous immuno-related events. Discussion and perspectivesThe occurrence of an immune-related event must be known and recognized with regard to its therapeutic impact, and be the subject of appropriate monitoring modalities. A more detailed knowledge of safety data and a better characterization of immune-related events will enable us to tailor our treatment pathways and proposals
Soussan, Sarah. « B lymphocytes and autoantibodies in immune-related adverse events following immune checkpoint inhibitors in cancer patients ». Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS022.pdf.
Texte intégralImmune checkpoints inhibitors (ICI) have revolutionized the treatment of previously incurable malignancies. Unfortunately, the use of ICI also induces a bystander breakdown of peripheral tolerance leading to immune related Adverse Events (irAEs) in 30-90% of treated patients, drastically reducing quality of life and requiring therapy dose reduction or discontinuation. As ICI directly target T cells, they have been considered the main culprit for irAEs. Nevertheless, T cells cannot fully explain adverse events, and the role of B cells and their associated mechanisms have not been characterized. We therefore studied the involvement of peripheral B-cell compartment in irAEs, using both phenotypic and functional approaches, in two cohorts of solid cancer patients treated with anti-PD-1 and/or anti-CTLA-4 monoclonal antibodies. Deep phenotyping of B-cell subsets throughout the treatment and at the onset of irAEs has been performed by multi-parametric spectral flow cytometry. Subsequently, to analyze the functions of B-cell subsets, notably their ability to produce antibodies, we set-up a B-cell culture system allowing in vitro differentiation of B cells into antibody-secreting cells. This gave us the opportunity to analyze the antibody production by circulating B cells and their association with irAEs occurence. The screening of circulating B cells phenotype and function was conducted alongside the evaluation of the serum and plasma reactivity of cancer patients by complementary approaches (ELISA, Western Blot, Immunofluorescence assays). We found that, before treatment, patients that develop ICI-induced irAEs exhibit a significantly lower expression on B cell subsets of the FcγRIIB, CD85j and LAIR-1 inhibitory receptors in melanoma patients and higher expression of the CD95 and CXCR5, respectively activating and lymphoid organs re-circulatory markers in lung cancer patients. In addition, increased in baseline abundance of hyper-activated IgD- memory B cell subset or plasmablasts precursor were observed in patients that will undergo irAEs. Moreover, a part of irAEs patients exhibit baseline or ICI-induce circulating autoantibodies which could be directed against the related tissue of irAEs occurrence. Indeed, patients experiencing cardiac/muscular irAEs demonstrated autoantibodies directed against cardiac tissues and well-defined cardiac/muscle antigens. Finally, IgG derived from cardiac/muscular irAEs patients bound to human cardiomyocytes and perturbed the calcium kinetic and the contractibility of cardiac spheroids. These findings highlight a predisposition of irAEs incidence in patients with baseline highly activated and differentiated circulating B cells associated with autoantibody production. Overall, these results support the potential role of the humoral adaptative immunity in the mechanisms of ICI-induced irAEs
Livres sur le sujet "Immune-related adverse effect"
J, Herzyk Danuta, et Bussiere Jeanine L, dir. Immunotoxicology strategies for pharmaceutical safety assessment. Hoboken, N.J : John Wiley & Sons, 2008.
Trouver le texte intégral1929-, Newcombe David S., Rose Noel R et Bloom John C, dir. Clinical immunotoxicology. New York : Raven Press, 1992.
Trouver le texte intégralBussiere, Jeanine L., et Danuta J. Herzyk. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons, Incorporated, John, 2008.
Trouver le texte intégralBussiere, Jeanine L., et Danuta J. Herzyk. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons, Incorporated, John, 2008.
Trouver le texte intégralImmunotoxicology Strategies for Pharmaceutical Safety Assessment. Wiley & Sons Canada, Limited, John, 2014.
Trouver le texte intégralDietert, Rodney R. Immunotoxicity Testing : Methods and Protocols. Humana Press, 2016.
Trouver le texte intégralCoyle, Patricia K. Immune-mediated Disorders of the Central Nervous System. Sous la direction de Emma Ciafaloni, Cheryl Bushnell et Loralei L. Thornburg. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190667351.003.0010.
Texte intégralChapitres de livres sur le sujet "Immune-related adverse effect"
Agolti, Mariela, et Lucrecia Solari. « Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment ». Dans Beyond Becquerel and Biology to Precision Radiomolecular Oncology : Festschrift in Honor of Richard P. Baum, 11–29. Cham : Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_2.
Texte intégralSaccardi, Riccardo, et Fermin Sanchez-Guijo. « How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified ? » Dans The EBMT/EHA CAR-T Cell Handbook, 199–201. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_38.
Texte intégralBhattacharyya, Joya, et Arthur Kaser. « Immune disorders of the gastrointestinal tract ». Dans Oxford Textbook of Medicine, sous la direction de Jack Satsangi, 2783–96. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0292.
Texte intégralDavicino, Roberto C., et Claudia Anesini. « Immunomodulatory Plant Extracts and their Compounds. Evaluation of your Safety ». Dans Advanced Pharmacy, 197–224. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815049428123010010.
Texte intégralBurton, Rosie, et Ana Houston. « HIV medicine ». Dans Oxford Handbook of Tropical Medicine 5e, 69–142. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198810858.003.0003.
Texte intégralRivera-Grana, Erick, et Stephanie M. Llop. « Immunotherapy-Associated Uveitis ». Dans Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106442.
Texte intégralPatel, Anush, Haisam Abid et Amrat Kumar. « The Endocrinological Side Effects of Immunotherapies ». Dans Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96491.
Texte intégralStrobel, Stephan, et Carina Venter. « Immune regulation, food allergies, and food intolerance ». Dans Human Nutrition. Oxford University Press, 2023. http://dx.doi.org/10.1093/hesc/9780198866657.003.0032.
Texte intégralMemis Bilgin, Yavuz. « Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation ». Dans Blood Donation and Transfusion [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.107228.
Texte intégralMoran, Carla. « Endocrine Complications of Biological Cancer Therapies ». Dans Oxford Textbook of Endocrinology and Diabetes 3e, sous la direction de John A. H. Wass, Wiebke Arlt et Robert K. Semple, 1774–78. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0218.
Texte intégralActes de conférences sur le sujet "Immune-related adverse effect"
Yenepalli, A., L. Luna Diaz et L. Eggert. « Asthma as an Immune-Related Adverse Effect of Pembrolizumab ». Dans American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5300.
Texte intégralVitek, Grace, et Harjot Hansra. « Two Cases of Anti-PD1 Antibody Associated Neurological Immune-Related Adverse Effects (P5-4.001) ». Dans 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000203811.
Texte intégralRichter, M. D., C. S. Crowson, L. A. Kottschade, H. D. Finnes, S. N. Markovic et U. Thanarajasingam. « SAT0588 Rheumatologic immune-related adverse effects of checkpoint inhibitor therapy : a single centrecohort of 29 patients ». Dans Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2645.
Texte intégralKandolf Sekulović, Lidija. « TOXICITIES OF TARGETED THERAPY AND IMMUNE-RELATED ADVERSE DRUG REACTIONS OF IMMUNOTHERAPY IN THE TREATMENT OF METASTATIC MELANOMA ». Dans Okrugli sto s međunarodnim učešćem "Melanom". Akademija nauka i umjetnosti Bosne i Hercegovine, 2018. http://dx.doi.org/10.5644/pi2019.180.04.
Texte intégralSklodowski, Kamil, Vito Dozio, Roberta Poli, Andrés Lanzós, Silvia Lopez-Lastra, Kristina Beeler et Emanuela Romano. « Abstract 1615 : Immune-related adverse effects (irAEs) associated proteomic profile in late-stage NSCLC patients after PD-1 blockade ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1615.
Texte intégralKostine, M., E. Mauric, L. Rouxel, T. Barnetche, R. Veillon, F. Martin, C. Dutriaux et al. « OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival : a single-centre prospective cohort study ». Dans Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3783.
Texte intégralMONBRUN, Mathilde, Léo Grassion, Elodie Blanchard, Rémi Veillon, Maeva Zysman et Chantal Raherison. « Influenza and Pneumococcal vaccination effects on the immune-related adverse events in patients under immunotherapy for an advanced stage non-small cell lung cancer ». Dans ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa2303.
Texte intégralBarreto, Everton Rodrigo, Rosana Maria Faria Vador et Thalita Martins Ferraz Meneses. « Nurse performance in viral oncolytic therapy ». Dans III SEVEN INTERNATIONAL MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/seveniiimulti2023-084.
Texte intégral